121 results about "IMMUNE FLUORESCENCE" patented technology

The invention relates to an integrated method for enriching and detecting a rare cell in a biological fluid sample. The enriching method comprises the following steps: (a) removing plasma protein by centrifugation; (b) optionally adding hematid lysis solution to carry out hematid lysis so as to remove hematid; (c) adding an immune microsphere or immune adsorbent to incubate; and (d) carrying out density centrifugation based on a specific cell separation medium so as to separate the a cycling rare cell, the residual cell after the hematid is removed and leucocyte combined on the immune microsphere. The method for detecting the enriched rare cells comprises the steps of combining pigmentation based on immune histochemistry or bi-color, tri-color or multicolor pigmentation based on the immunehistochemistry with immune fluorescence and observing and identifying by a fluorescent or common optical microscope or a scanner based on a microscope principle. The novel and unique method for enriching and detecting a rare cell in a biological fluid sample is proved to have low cost and can rapidly, effectively and highly specifically enrich and quantitatively detect the rare cell in blood.

The invention provides a method for carrying out fast effective separation of red blood cells and non-blood-borne nucleated cells from human biological fluid. According to the method, red blood cell cracking and melting are not needed, and no influence is caused upon target cells (such as tumor cells in the body fluid) in human body fluid, such that original cell morphology is well maintained, and subsequent cell identification and determination are facilitated. The invention also relates to a method for discriminating non-blood-borne nucleated cells (such as tumor cells, vascular endothelial cells, and the like) enriched from human or animal biological fluid. According to the invention, anti-human leukocyte antibody immune-fluorescence staining and chromosome fluorescence in-situ hybridization are carried out concurrently, such that blood-borne nucleated cells are discriminated, and blood-borne nucleated cell interference during a tumor cell determination process is effectively eliminated. Therefore, non-blood-borne epithelial-source (solid tumor) or non-epithelial-source (melanoma) rare tumor cells can be enriched, extracted, and effectively discriminated from human body fluid rapidly with high efficiency.